Safety Profile and Adverse Events of Special Interest for Fruquintinib in Chinese Patients with Previously Treated Metastatic Colorectal Cancer: Analysis of the Phase 3 FRESCO Trial

被引：0

作者：

Jin Li

Weijian Guo

Yuxian Bai

Yanhong Deng

Lei Yang

Zhendong Chen

Haijun Zhong

Ruihua Xu

Hongming Pan

Yongqian Shu

Ying Yuan

Jianfeng Zhou

Nong Xu

Tianshu Liu

Dong Ma

Changping Wu

Ying Cheng

Jianming Xu

Donghui Chen

Wei Li

Sanyuan Sun

Zhuang Yu

Peiguo Cao

Lin Shen

Haihui Chen

Shubin Wang

Hongbing Wang

Songhua Fan

Xiaojun Guo

Ning Wang

Rubing Han

Bin Zhang

Shukui Qin

机构：

[1] Tongji University East Hospital,Department of Medical Oncology

[2] Fudan University Shanghai Cancer Center,Department of Medical Oncology, Shanghai Medical College

[3] Harbin Medical University Cancer Hospital,Department of Medical Oncology

[4] The Sixth Hospital Affiliated to Sun Yat-sen University,Department of Medical Oncology

[5] Nantong Cancer Hospital,Department of Medical Oncology

[6] The Second Hospital of Anhui Medical University,Department of Medical Oncology

[7] Zhejiang Cancer Hospital,Department of Medical Oncology

[8] Sun Yat-sen University Cancer Center,Department of Medical Oncology

[9] Sir Run Run Shaw Hospital,Department of Medical Oncology

[10] Jiangsu Provincial Hospital,Department of Medical Oncology

[11] The Second Affiliated Hospital of Zhejiang University,Department of Medical Oncology

[12] Peking Union Medical College Hospital,Department of Oncology

[13] The First Affiliated Hospital Zhejiang University College of Medicine,Department of Medical Oncology

[14] Fudan University Zhongshan Hospital,Department of Medical Oncology

[15] Guangdong Provincial People’s Hospital,Department of Medical Oncology

[16] The First People’s Hospital of Changzhou,Department of Medical Oncology

[17] Jilin Province Cancer Hospital,Department of Medical Oncology

[18] The Fifth Medical Center of Chinese,Department of Medical Oncology

[19] PLA General Hospital,Department of Medical Oncology

[20] Shanghai Jiao Tong University Affiliated First People’s Hospital,Department of Medical Oncology

[21] The First Hospital of Jilin University,Department of Medical Oncology

[22] Xuzhou Central Hospital,Department of Medical Oncology

[23] The Affiliated Hospital of Medical College Qingdao University,Department of Medical Oncology, Xiangya Hospital of Central South University

[24] The Third Xiangya Hospital of Central South University,Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education)

[25] Peking University Cancer Hospital & Institute,Department of Medical Oncology

[26] Liuzhou Worker’s Hospital,Department of Medical Oncology

[27] Beijing University ShenZhen Hospital,Department of Medical Oncology

[28] Beijing University,undefined

[29] The Affiliated Hospital of Xuzhou Medical College,undefined

[30] Xuzhou Medical College,undefined

[31] Hutchison MediPharma Limited,undefined

[32] Lilly China,undefined

[33] Drug Development and Medical Affairs Center,undefined

[34] Cancer Center of Jinling Hospital,undefined

来源：

Advances in Therapy | 2020年 / 37卷

关键词：

Adverse events of special interest; Chinese patients; FRESCO trial; Fruquintinib; Metastatic colorectal cancer; Safety profile;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：4585 / 4598

页数：13

共 88 条

[1] Haggar FA(2009)Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors Clin Colon Rectal Surg 22 191-197
[2] Boushey RP(2017)Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the Global Burden of Disease Study JAMA Oncol 3 524-548
[3] Fitzmaurice C(2017)Global patterns and trends in colorectal cancer incidence and mortality Gut 66 683-691
[4] Allen C(2012)Increased burden of colorectal cancer in Asia World J Gastrointest Oncol 4 68-70
[5] Arnold M(2016)Cancer statistics in China, 2015 CA Cancer J Clin 66 115-132
[6] Sierra MS(2015)Metastatic colorectal cancer: current state and future directions J Clin Oncol 33 1809-1824
[7] Laversanne M(2015)Clinical outcomes of Chinese patients with metastatic colorectal cancer receiving first-line bevacizumab-containing treatment Med Oncol 32 469-1920
[8] Soerjomataram I(2016)Advances in targeted and immunobased therapies for colorectal cancer in the genomic era Onco Targets Ther 9 1899-259
[9] Jemal A(2016)Colorectal cancer: overcoming resistance to anti-EGFR therapy—where do we stand? Nat Rev Gastroenterol Hepatol 13 258-70
[10] Bray F(2015)Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: toward targeted personalized therapy Drug Resist Updat 20 39-529

← 1 2 3 4 5 6 7 8 9 →